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Abstract
Viruses have evolved several strategies to modify cellular processes and evade the immune response in order to successfully
infect, replicate, and persist in the host. By utilizing in-silico testing of a transmembrane sequence library derived from virus
protein sequences, we have pin-pointed a nine amino-acid motif shared by a group of different viruses; this motif resembles
the transmembrane domain of the a-subunit of the T-cell receptor (TCRa). The most striking similarity was found within the
immunodeficiency virus (SIV and HIV) glycoprotein 41 TMD (gp41 TMD). Previous studies have shown that stable
interactions between TCRa and CD3 are localized to this nine amino acid motif within TCRa, and a peptide derived from it
(TCRa TMD, GLRILLLKV) interfered and intervened in the TCR function when added exogenously. We now report that the
gp41 TMD peptide co-localizes with CD3 within the TCR complex and inhibits T cell proliferation in vitro. However, the
inhibitory mechanism of gp41 TMD differs from that of the TCRa TMD and also from the other two known
immunosuppressive regions within gp41.
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Introduction
The transmembrane domains (TMDs) of the T-cell receptor
(TCR) play an important role in the assembly of the receptor
complex. The mosaic assembly of the TCR complex, composed of
the TCR-a and b subunits and the invariant CD3 co-receptor
chains, gives rise to one of the most remarkable and complex
receptor structures. A unique characteristic of the multi-protein
receptor assembly is the presence of nine potentially charged and
conserved amino-acid residues within the transmembrane helices
of both the TCR and the CD3 co-receptor [1–3]. It has been
shown that one basic and two acidic transmembrane residues,
within these nine residues, are required for the assembly of each of
the three CD3 signaling dimmers (d-e, c-e, f-f) with the TCR [4].
In concert with the latter, Manolios et al have shown that the stable
interactions between the TCRa and CD3 are localized to a short
region within the transmembrane domain of TCRa. Moreover,
they have shown that the charged amino acids arginine and lysine
are essential for this interaction [5–7]. In addition, a nine amino-
acid peptide derived from the TCRa transmembrane domain,
which includes these two charged amino acids (TCRa TMD,
GLRILLLKV), interfered and intervened in the TCR function
when added exogenously [8].
An important question is whether viruses have exploited this
mechanism to interfere with the TCR complex assembly in
order to modify T-cell function and thereby evade immune
surveillance and enhance viral infection, replication and
persistence. Recent studies with HIV support this notion.
Similar to other enveloped viruses, HIV requires a fusion of
the viral membrane and the cellular membrane to initiate
infection. For that purpose it employs a fusion protein, the
transmembrane gp41 (gp41) that is non-covalently linked to the
surface glycoprotein 120 (gp120). Together, gp120 and gp41
form the enveloped glycoprotein complex, gp160, [9] which is
embedded in the viral membrane as a trimmer [10]. The surface
gp120 is primarily involved in binding to cellular receptors,
whereas gp41 is anchored to the viral membrane and mediates
membrane fusion.
Gp41 is composed of cytoplasmic, transmembrane, and extra-
cellular domains [11–15]. The extra-cellular domain (ectodomain)
contains four major functional regions including a stretch of 16
hydrophobic residues, located at the N terminus, referred to as the
‘‘fusion peptide’’ (FP) [12,13] (Figure 1). During the initial step of
T-cell infection, gp120 binds to the CD4 molecule, which is part of
the T-cell receptor complex. The FP then anchors gp41 to the
target membrane and initiates the fusion process [15–19].
However, it has been shown that anchoring gp41 to the target
cell serves not only the purpose of supporting a successful fusion,
but also suppresses the ability of the T-cell to be activated and
proliferate. FP gains this activity by specifically binding to the
TMD of TCRa and interfering with the assembly of the TCR
complex; [20–23]. Another known immunosuppressive (ISU)
region is composed of amino acids 583–599, but its mode of
action is not known [24] (Figure 1 and Table 1).
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group of different viruses and compared it to the TMD of TCRa.
The most striking resemblance to the TCRa TMD, including the
important arginine residue, was found within the immunodefi-
ciency virus (SIV and HIV) glycoprotein 160 TMD (gp41 TMD).
This suggests a role for the TM domain in T-cell suppression as
well. To test this hypothesis, we synthesized a peptide comprising
the gp41 TM region and examined its immunosuppressive activity
and a plausible mode of action. The results indicate that gp41
TMD co-localizes with CD3 within the TCR molecule and
inhibits T-cell proliferation in-vitro. This effect is specific to the
TCR complex, since T-cell activation by PMA/ionomycin is not
affected by gp41 TMD. Interestingly, the mechanisms by which
the other two immunosuppressive peptides express their activities
are different: FP inhibits antigen-specific T-cell proliferation by
specifically interacting with the TCRa subunit [23], whereas the
ISU inhibits T-cell proliferation induced by anti-CD3 and PMA/
ionomycin [24]. Detailed understanding of the molecular
interactions mediating the immunosuppressive activity of the
gp41 TMD should facilitate the evaluation of its contribution to
HIV pathology. Disassociated from HIV, however, the gp41
TMD molecule provides a novel mechanism for down regulating




The nine amino-acid sequence, GLRILLLKV, derived from
the TCRa TMD (designated TCRa CP) could interfere with TCR
function [8]. In order to examine whether viral protein repertoires
contain TMD sequences that are homologous to this immuno-
suppressive sequence, we took advantage of the Uniport
Knowledge Base to construct a viral TMD sequence library. To
do this, we performed a systematic pairwise alignment using the
EMBOSS package : Needle global alignment [25]. Our results
indicated that the top-ranked sequence belongs to the TMD of the
SIV gp160 Envelope protein (Figure 2A.I, Entry, accession
number: Q8AIH5). This TMD (21 aa) contains a 9 aa sequence
with 88.9% similarity and 66.7% identity to the TCRa CP. All the
sequence entries (n.3) belonging to a distinct species have been
grouped into 265 TMD clusters (over all 2874 sequence entries).
Figure 2B displays the averaged normalized Z-score distribution of
each cluster. Interestingly, the top-four ranked viral protein
Figure 1. HIV-1 gp41 extra-cellular domain. A scheme showing the functional regions within the extra-cellular portion of gp41 (aa 512–684).
doi:10.1371/journal.ppat.1001085.g001
Author Summary
HIV uses several mechanisms that allow it to evade
immune control, in order to successfully infect, replicate,
and persist in the host. Here we report a new mechanism.
We utilized bioinformatics and identified a region within
the transmembrane domain (TMD) of the envelop proteins
of viruses that has high similarity with the a subunit of the
T-cell receptor (TCR) TMD. A striking similarity was found
within the immunodeficiency virus (SIV and HIV) glyco-
protein 41 (gp41). TCR TMDs play an important role in the
assembly of the receptor complex composed of the TCR
subunits and the CD3 co-receptor chains. We show that a
synthetic peptide derived from gp41 TMD co-localizes with
CD3 and inhibits T-cell proliferation in vitro. Biophysical
studies suggest a specific interaction between gp41 TMD
and the TMD of the TCRa subunit. Importantly, the
inhibitory mechanism of gp41 TMD differs from that of
the other two known immunosuppressive regions within
gp41. Overall, the present study demonstrates a new
weapon that HIV-1 uses to penetrate into the host cell and
modulates its immune response. Disassociated from HIV,
however, HIV TMD molecule provides a novel mechanism
for down regulating undesirable responses and might be
used as a new therapy for autoimmune diseases.
HIV-1 gp41 TM Inhibits T-Cell Proliferation
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HIV-1 gp41), Feline immunodeficiency virus (FIV) gp150 and two
TMDs within the latent membrane protein 1 (LMP1) from
Epstein-Barr virus (EBV). Despite the fact that a single sequence
entry within the SIV gp160 cluster (Accession number: Q8AIH5)
was the top ranked alignment, the SIV gp160 cluster was ranked
lower.
To statistically test the observation that HIV-1 gp41 TMD
cluster was significantly ranked higher, a Wilcoxon Rank Test was
performed. As shown in Figure 2C, the HIV-1 gp41 TMD cluster
was significantly higher ranked than all the other clusters that were
not included within this top four group (FIV gp150 and EBV
LMP1).
Gp41 TMD inhibits T-cell proliferation in-vitro
Our in-silico analysis revealed that four viral protein clusters
were significantly ranked in comparison with all the other clusters
within our TMD library. As HIV/T-cell interactions are central to
HIV infection, we reasoned that these findings may aid in further
characterizing the process of HIV infection. The initial step was to
examine whether the gp41 TM region, like the TCRa CP, is able
to inhibit T-cell proliferation in-vitro. For that purpose we prepared
lymph node cells from mice immunized with MOG 35–55/CFA
(MOG 35–55-immunized) and studied their T-cell responses to
the MOG 35–55 peptide. The MOG 35–55 peptide induced
strong proliferative responses and cytokine release from T-cells in
the draining lymph node cells of MOG 35–55-immunized mice.
We then synthesized a peptide derived from one of the top ranked
HIV-1 gp41 TM entries (Figure 2AII, Accession number: P03378,
Table 1). Next, we incubated the peptide in the presence of MOG
p35–55 antigen with a T-cell line that is specific to MOG p35–55
anddeterminedtheproliferativeresponsesafter3daysofincubation,
using a H3-thymidine uptake assay. Figure 3 shows that the peptide
exhibited dose-dependent inhibition of T-cell proliferation.
The concentration of gp41 TMD in the cell membrane is very
small. However, gp41 contains two more immunosuppressant
regions (FP and ISU) which probably act synergistically and
rapidly with the gp41 TMD. In addition, these regions are
directed to the TCR complex after binding of gp120 to the CD4
and co-receptors. In contrast, the gp41 TMD peptide investigated
here lacks a receptor, and in addition it is only part of the gp41
complex. This requires much higher concentrations of the peptide
to obtain a significant immunosuppressant activity.
Gp41 TMD inhibits T-cell activation induced by
antibodies to CD3
To determine whether gp41 TMD can also inhibit T-cell
activation other than that induced by APC presentation of specific
antigen, we tested the effect of gp41 TMD on T-cell activation
induced by a mitogenic monoclonal antibody to CD3. TCRa CP
served as a control peptide. Gp41 TMD unlike TCRa CP [8],
inhibits the activation of T-cells by mitogenic anti-CD3 (Figure 4).
Mitogenic anti-CD3 antibodies activate CD3 signaling regardless
of the presence or absence of TCR [22]. These results suggest that
gp41 TMD interacts with the CD3, although we cannot rule out
other, indirect interactions.
Gp41 TMD does not inhibit T cell activation induced by
PMA/ionomycin
To learn whether gp41 TMD can also inhibit T-cell activation
other than that induced by APC presentation of specific antigen or
mitogenic monoclonal antibody to CD3 (the TCR complex), we
tested the effect of gp41 TMD on T-cell activation induced by
PMA/ionomycin. Gp41 TMD, like TCRa CP, did not inhibit the
activation of T-cells by PMA/ionomycin (Figure 5). PMA/
ionomycin activates the T-cell downstream to the membrane
regardless of the presence or absence of the TCR [3]. These
findings suggest that gp41 TMD inhibits T-cell activation by
interfering with the TCR and CD3 proper function.
Gp41 TMD co-localizes with the CD3 and TCR
We utilized confocal microscopy to further support our findings
that the gp41 TMD peptide interacts specifically within the TCR
complex and does not home to the cytoplasm. It has been reported
that the TCR, CD3, and CD4 receptors, among other
components, are localized in micro-domains in the membranes
of activated CD4+ T cells [2]. Using Sy5 labeled antibodies to the
CD3 molecules, we examined the localization and distribution of
the CD3 molecules in the membranes of resting and activated T-
cells. In resting T-cells, the CD3 molecules were found in micro-
domains all around the T-cell, while the distribution of the CD3
molecules resembled a capping shape in activated T-cells
(Figure 6A). In order to examine the distribution of gp41 TMD
in the membrane of resting and activated mice T cells, we used
gp41 TMD peptide conjugated to the fluorescent probe 4-chloro-
7-nitrobenz-2-oxa-1, 3-diazole (NBD; gp41 TMD-NBD). Rather
then uniformly labeling the T-cell membrane, the gp41-TMD
NBD showed a heterogeneous membrane distribution and a
capping shape on the membrane of activated T-cells. This
distribution in membrane domains contrasted with that of a
control membrane-active amphipathic peptide conjugated to NBD
(AMP-NBD), which demonstrated a uniform distribution and no
capping shape on activated T-cell membranes (Figure 6A). In
contrast to the AMP-NBD control peptide, the gp41-TMD
conjugates exhibited the same distribution pattern as the CD3
molecules. In the next step, we demonstrated that the gp41 TMD
not only showed the same distribution pattern but also had a
significantly higher percentage of co-localization with the CD3
molecules (58.8%, Figure 6B) compared to the AMP-NBD control
peptide (27%, Figure 6C) (p,0.05).
Fluorescence Energy Transfer (FRET) measurements
reveal a specific interaction between gp41 TMD and
TCRa CP
We labeled the TCRa CP peptide with NBD as the donor
fluorophore, and both gp41 TMD and TCRa CP peptides with
Rho-TAMRA as the acceptor fluorophore. In addition, we also
labeled an unrelated transmembrane peptide derived from the
E.coli aspartate receptor (TAR/PS) as a control hydrophobic
peptide (Table 1). We then measured the fluorescence energy
transfer (FRET) between fluorescently labeled TCRa CP-NBD
peptide and gp41 TMD – Rho (7A), TCRa CP-Rho (7B) or
Table 1. Designations and Sequences of the Peptides
Investigated in This Study.
Designation sequence
full length gp41 TMD KKKLFIMIVGGLVGLRIVFAVLSIKKK
TCRa CP GLRILLLKV
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environment of large unilamellar vesicles (LUV) composed of PC
phospholipids. Four ratios of Rho-peptide:NBD-peptide were
used: 0:4, 1:4, 2:4 and 3:4. The TCRa CP-NBD peptide showed
about ,50% energy transfer in the presence of the gp41 TMD -
Rho peptide at an acceptor-to-lipid ratio of 1:1000 (Figure 7A),
indicating an interaction between the two peptides. When we
examined the energy transfer of TCRa CP-NBD peptide in the
presence of TCRa CP-Rho peptide, there was lower energy
transfer (,37%, 7B). The TAR/PS – Rho control peptide did not
show energy transfer (7C).
Discussion
During evolution, viruses have evolved various strategies to
modify cellular processes and evade immune responses, which
allow them to successfully infect, replicate, and persist in the host.
Here we utilized bioinformatic tools to identify a new region
corresponding to the TMD of the HIV-1 gp41 ENV glycoprotein
that enables the virus to inhibit T-cell proliferation. We identified
viruses that contain sequences within their TM region that are
similar to TCRa CP, an immunosuppressant domain within the
TCRa TMD (Figure 2). The results revealed four viral protein
Figure 2. Bioinformatics database analysis. A. The sequence alignments obtained from the EMBOSS package: Needle global alignment analysis.
I) TCRa CP / SIV gp41 TMD sequences alignment II) TCRa CP / HIV-1 gp41 TMD sequences alignments. B. Z-Score alignment histogram. TMD Entries
scores were clustered according to taxonomic species division. The mean of each cluster was Z-normalized. The histogram describes the distribution
of alignment scores over the 265 clusters dataset C. Wilcoxon Rank Test. The HIV-1 gp41 cluster (n=47) was compared against all the other 264
clusters using Wilcoxon Rank Test. p-value results of comparisons are presented in a log scale. Significance of ranking was determined according to
Benjamini-Hochberg method (E (FDR),0.05). Clusters which are significantly lowered ranked over HIV-1 gp41 are marked (black dot) and presented
left to the arrow. Cluster which were not significantly distinct in ranking from HIV-1 gp41 are marked (diamond).
doi:10.1371/journal.ppat.1001085.g002
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within EBV LMP1, that were significantly ranked in comparison
with all other TMDs within our library (Figure 2C).
Dukers et al. have reported that purified recombinant EBV
LMP1 suppress activation of T-cells. They found that a 7-amino
acid peptide (LALLFWL) within the TMD1 of EBV LMP1 has
immunosuppressant activity [26]. However, this region does not
overlap with the EBV LMP1 TMD1 cluster that emerged from
our bioinformatic analysis (GLALLLLLL). Interestingly, within
our top four highest ranked clusters we identified another EBV
LMP1 TMD region within the TMD3 (GLGLLLLMV). Howev-
er, since HIV/T-cell interactions are central to HIV infection, it
was most interesting to investigate whether the HIV-1 gp41 may
be exploited by HIV to modulate and interfere with T-cell
activation.
Gp41 TMD is one of the most conserved regions within the
gp41 sequence [27]. Studies have suggested that this region is
involved in many important biological functions such as anchoring
of the Env glycoprotein in both viral and cellular membranes [28],
cell-cell fusion [29] and in the mixing and fusion of phospholipids
between two lipid vesicles [30]. The fact that T-cells are targets of
HIV-1 raised the question whether this TMD is also exploited by
the virus to modulate the T-cell immune response. Strikingly, we
found that a synthetic peptide resembling the gp41 TMD is able to
co-localize with the TCR complex and suppress T-cell prolifer-
Figure 3. Gp41 TMD inhibits T-cell proliferation in vitro. T-cells were activated with the MOG 35–55 peptide and APC in the presence of gp41
TMD (black) or FP5–13 AAAA as control peptide (grey) in three different concentrations (50, 25 and 5 mg/ml) and the proliferative responses were
assayed. The data are presented as mean inhibitions+SD (n=4 or more, ** p,0.01). The uninhibited T-cell proliferative responses were
93826891 cpm. The background proliferation in the absence of antigen was 232636 cpm.
doi:10.1371/journal.ppat.1001085.g003
Figure 4. Gp41 TMD inhibit T-cell activation induced by
mitogenic antibodies to CD3. T-cells were activated with 1mg/ml
anti-CD3 and APC in the presence of 50mg/ml gp41 TMD or TCRa CP
and the proliferative responses were assayed. The uninhibited T-cell
proliferative responses were 91036208 cpm. The background prolifer-
ation in the absence of antigen was 257641 cpm. The data are
presented as normalized mean proliferation percentage (control, no
peptide=100%) + SD (n=5 or more, ** p,0.01). There was no
significant statistical difference between the TCRa CP and the control.
doi:10.1371/journal.ppat.1001085.g004
Figure 5. Gp41 TMD does not inhibit T-cell activation induced
by PMA/ionomycin. T cells were stimulated with PMA/ionomycin or
in the presence of gp41 TMD or TCRa CP, and T cell proliferation was
studied. The uninhibited T-cell proliferative responses were
122206871 cpm. The background proliferation in the absence of
antigen was 246638 cpm. The data are presented as normalized mean
proliferation percentage (control, no peptide=100%)+SD (n=5 or
more). There was no significant statistical difference between all groups.
doi:10.1371/journal.ppat.1001085.g005
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immunosuppressive region.
It has been shown previously that the HIV-1 gp41 has two other
immunosuppressive regions: FP [21–23] and ISU [24]. The
mechanisms by which these two immunosuppressive regions
express their activity are different: FP inhibits antigen-specific T-
cell proliferation by specifically interacting with the TCRa [23],
whereas ISU inhibits T-cell proliferation induced by anti-CD3 and
PMA/ionomycin [24].
To better understand the mechanism by which the TM region
exerts its immunosuppressive activity, we examined the abilities of
the gp41 TM peptide to inhibit T-cell proliferation when triggered
through different signal-transduction cascades. Interestingly, we
found that gp41 TMD, unlike the FP [21,23] or TCRa CP [8],
inhibits T-cell activation induced by mitogenic antibodies specific
for the CD3 molecule (Figure 4). This interaction activates T cells
regardless of their TCR and is downstream of the TCR activation
pathway. This is despite the fact that this TM peptide has high
homology to TCRa CP as found through bioinformatic analysis.
To follow the mode of action underlying the latter inhibition, we
further examined the interaction between gp41 TMD and TCRa
CP by using FRET. The data summarized in Figure 7 reveal a
direct interaction between these two TMDs. Note that gp41 TMD
did not inhibit T-cell activation triggered by PMA/ionomycin.
Overall the data support the notion that gp41 TMD most likely
interacts with the TCR complex in a way that interferes with both
the TCR and CD3 proper function. Our confocal microscopy
results indicate that the gp41 TMD-mediated interference is likely
to occur within the cell membrane since the peptide is not
detectable elsewhere (Figure 6).
As discussed previously, the immunosuppressive domain (ISU)
in gp41 (Figure 1 and Table 1) is capable of inhibiting T-cell
activation [24]. Similarly to gp41 TMD, the ISU inhibits T-cell
activation triggered by CD3-specific antibodies [24]. However, in
contrast to gp41 TMD, ISU can also inhibit T-cell activation
triggered by PMA/ionomycine [31]. Thus, ISU simultaneously
targets protein kinase C activity [32] and the events related to T-
cell activation that occur within the cell membrane [33]. In
contrast, gp41 TMD only targets T-cell activation within the cell
membrane. Hence, gp41 equips HIV-1 with at least 3 different
inhibitors of T cell activity: gp41 TMD, FP and ISU. Each of them
uses a different mode of action, which we propose can function at
different time points during viral infection.
In addition to the inhibitors described above, it has been also
reported that HIV-1 impairs T-cell activation and immunological
synapse formation between infected lymphocytes and antigen-
presenting cells (APCs) by Nef (negative factor) mediation [34–36].
One may reason that inhibitors of T-cell activation in general,
such as that mediated by Nef and gp41 TMD in particular, may
also inhibit the successful replication of the virions, since the
Figure 6. Gp41 TMD co-localizes with CD3 within the TCR complex. Gp41 TMD-NBD and AMP-NBD were used to study peptide binding to
the membranes of resting and activated T cells in combination with Sy5-labeled antibodies to CD3. The T cells had been activated by incubation with
APC and the MOG 35–55 peptide. (A) Distribution of gp41 TMD-NBD, AMP-NBD and CD3 molecules in resting and activated T cells. (B) Co-localization
of gp41 TMD-NBD with the CD3 molecules. (C) Co-localization of AMP-NBD with the CD3 molecules.
doi:10.1371/journal.ppat.1001085.g006
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their activation state [37]. However, despite the fact that infection
is much more efficient in activated T-cells, replication of HIV-1
and simian immunodeficiency virus (SIV) in-vivo occurs in T-cells
that display a low activation profile as well [38–41]. Since we used
a high concentration of gp41 TMD peptide (5–50mg/ml), we
believe that the effect in vivo might be a modulation of the T-cell
activity rather than total inhibition.
It has been reported that lymphocyte activation, through TCR
ligation or other stimuli, frequently leads to homeostatic
programmed apoptosis [42,43]. Therefore, it is not unlikely that
the gp41 ENV expression in vivo may lead to apoptosis due to TM-
TM interactions of the gp41 and the TCR complex that modulate
the appropriate signaling. The rapid death of the infected cells will
most certainly limit the production of the virus. For that reason, in
order to ensure its spread, the virus must establish a balance
between the apoptosis-prone activation state and the replication-
unfavorable environment of resting cells.
Although it is still unclear how these target cell effects are related
to the replication efficiency of the virus, various viral proteins are
known to be involved in these phenomena. For example, Nef and
Tat (transcriptional transactivator) are known to modulate T-cell
activity, which is likely to facilitate viral replication [35,44–46].
Therefore, the fact that gp41 TMD inhibits or modulates T-cell
activity does not necessarily imply that viral replication is decreased.
The presence of gp41 on the cell membrane prior to and during
budding may interfere with the ability of infected T cells to
proliferate, thus allowing the virus to harness most cellular resources
for its own needs. Hence, we suggest here that HIV-1 can utilize
gp41 TM inhibitory mechanism to facilitate viral replication and to
enable an efficient budding of the virions.
As we reported earlier, HIV-1 uses the FP in the N terminus of
gp41 for anchoring to the target cell and to inhibit T cell activation
[21,23]. We show here that gp41 TMD interacts with CD3 and
TCRa. Therefore, it is likely that gp41 TMD is also located within
the TCR-FP region during the membrane fusion phase and for
that reason may have a role in an efficient fusion process and as an
alternative mechanism to ensure that the T cell will not be
activated during this central step of infection. However, further
experiments are required to better understand the mechanisms by
which the virus modulates signaling within the infected cell. Note
that an interesting theoretical model published recently try to
explain TCR modulation by the appearance of two electro-
positively charged residues within virus fusion peptides causing
electrostatic disturbance within the complex [47].
It has been argued recently that HIV-1 and microvsicles from T
cells share a common glycome, which may indicate a common
origin [48]. Our in silico results pinpoints a high similarity between
the gp41 TM region and the TCRa TMD region (CP domain). In
addition, the similarity between gp41 TMD and TCRa CP was
found to be of far greater significance than that between other
virsues’ TMD and TCRa CP. Therefore, the question regarding
the origin of this sequence is still unclear.
In summary, the present study demonstrates a new weapon that
HIV-1 uses to penetrate into the host cell and modulates its
immune response. This immunosuppressive activity of gp41 TMD




All animal experiments were conducted at the Weizmann
Institute of Science and approved by the Weizmann Institutional
Figure 7. Fluorescence Energy Transfer (FRET) measurements
reveal a specific interaction of the gp41 TMD and the TCRa CP.
Fluorescence spectra were obtained at room temperature, with
excitation set at 467 nm (5-nm slit) and emission scan at 500–600 nm
(10-nm slits). NBD-labeled CP peptide was added first from a stock
solution in DMSO (final concentration 0.1 mM and a maximum of 0.25%
(v/v) DMSO) to a dispersion of PC LUV (100 mM) in PBS. This was
followed by the addition of: A. Rho labeled gp41 TMD peptide B. Rho
labeled TCRa CP C. Rho labeled TAR/PS TM control peptide.
Fluorescence spectra were obtained in four different ratios of Rho-
peptide:NBD-peptide: 0:4 (black line), 1:4 (black triangle), 2:4 (black
circle) and 3:4 (dashed line). The fluorescence values were corrected by
subtracting the corresponding blank (buffer with the same vesicles
concentration). Statistical analysis was performed at the pick measure-
ments (,537 nm, n=5, * p,0.05).
doi:10.1371/journal.ppat.1001085.g007
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law and the National Research Council guide (Guide for the Care
and Use of Laboratory Animals 2010).
Materials
Rink amide MBHA resin and 9-fluorenylmethoxycarbonyl
(Fmoc) amino acids were purchased from Calibochem-Novabio-
chem AG (Switzerland). Other reagents used for peptide synthesis
include N,N-diisopropylethylamine (DIEA, Aldrich), dimethyl-
formamide, dicheloromethane, and piperidine (Biolab, IL). Egg
phosphatidylcholine (PC) was purchased from Lipid Products
(South Nutfield, UK). 4-chloro-7-nitrobenz-2-oxa-1,3-diazole
fluoride (NBD-F) and rhodamine-N-hydroxysuccinimide (Rho-
N) were purchased from Molecular Probes (Junction City, OR,
USA). The myelin oligodendrocyte glycoprotein (MOG) p35–55
antigen used for the specific activation of the T-cell line was
synthesized using the Fmoc technique with an automatic multiple
peptide synthesizer (AMS 422, ABIMED, Langenfeld, Germany).
The Hamster anti-mouse anti-CD3 antibody was collected by
trichloroacetic acid (TCA) precipitation from 2C11 hybridoma
supernatant.
Peptide synthesis and fluorescent labeling
Peptides were synthesized using the Fmoc solid phase method
on Rink amide resin (0.68 meq/gm), as previously described [49].
The synthetic peptides were purified (greater than 98% homoge-
neity) by reverse phase high performance liquid chromatography
(RP-HPLC) on a C4 column using a linear gradient of 30–70%
acetonitrile in 0.1% trifluoroacetic acid (TFA) for 40 minutes. The
peptides were subjected to amino acid and mass spectrometry
analysis to confirm their composition. To avoid aggregation of the
peptides prior to their use in the cell culture assays, the stock
solutions of the concentrated peptides were maintained in
dimethyl sulfoxide (DMSO). The final concentration of DMSO
in each experiment was lower than 0.25% vol/vol and had no
effect on the system under investigation. For NBD-F fluorescent
labeling, resin-bound peptides were treated with NBD-F (2-fold
excess) dissolved in dimethyl formamide (DMF), leading to the
formation of resin-bound N-terminal NBD peptides [50]. After
1 h, the resins were washed thoroughly with DMF and then with
methylene chloride, dried under nitrogen flow, and then cleaved
for 3 h with TFA 95%, H2O 2.5%, and triethylsilane 2.5%. For
Rho-N fluorescent labeling, the Fmoc protecting group was
removed from the N-terminus of the resin-bound peptides by
incubation with piperidine for 12 min, whereas all the other
reactive amine groups of the attached peptides were kept
protected. The resin-bound peptides were washed twice with
DMF, and then treated with rhodamine-N-hydroxysuccinimide (2-
fold excess), in anhydrous DMF containing 2% DIEA, leading to
the formation of a resin-bound N-rhodamine peptide. After 24 h,
the resin was washed thoroughly with DMF and then with
methylene chloride, dried under nitrogen flow, and then cleaved
for 3 h with TFA 95%, H2O 2.5%, and triethylsilane 2.5%.The
labeled peptides were purified on a RP-HPLC C4 column as
described above. Unless stated otherwise, stock solutions of
concentrated peptides were maintained in DMSO to avoid
aggregation of the peptides prior to use.
Preparation of Large Unilamellar Vesicles (LUV)
Thin films of PC were generated after dissolving the lipids in a
2:1 (v/v) mixture of CHCL3/MeOH and drying them under a
stream of nitrogen gas while rotating them. The films were
lyophilized overnight, sealed with argon gas to prevent oxidation
of the lipids, and stored at 220uC. Before the experiments, films
were suspended in the appropriate buffer and vortexed for
1.5 min. The lipid suspension underwent five cycles of freezing-
thawing and extrusion through polycarbonate membranes with 1-
and 0.1-mm diameter pores to create large unilamellar vesicles.
Fluorescence Energy Transfer (FRET) measurements
The FRET experiments were performed by using NBD and
Rho labeled peptides. Fluorescence spectra were obtained at room
temperature, with excitation set at 467 nm (10-nm slit) and
emission scan at 500–600 nm (10-nm slits). In a typical
experiment, a NBD-labeled peptide was added first from a stock
solution in DMSO (final concentration 0.1 mM and a maximum of
0.25% (v/v) DMSO) to a dispersion of PC LUV (100 mM) in PBS.
This was followed by the addition of Rho labeled peptide in
several sequential doses ranging from 0.025 mM to 0.075 mM
(stock in DMSO). Fluorescence spectra were obtained before and
after addition of the Rho labeled peptide. The fluorescence values
were corrected by subtracting the corresponding blank (buffer with
the same vesicles concentration). The statistical analysis was
performed using ANOVA for the pick measurements at 535nm
(n=3, * p,0.05).
Co-localization of peptides with TCR molecules
Resting MOG35–55 T-cells or after activation for 72 h with
MOG35–55 and APC were blocked with 1% BSA at room
temperature to block non-specific binding. After 30 min the cells
were washed and divided into aliquots containing 100,000 cells per
100 ml, and either gp41 TMD or a control membrane-binding
peptide (AMP-scr) was added (final concentration of 2mM) for 1 h
at 37uc. The cell were then washed and labeled with the tested
antibody for 25min at RT followed by biotin-conjugated anti-
hamster IgG 25min at RT and Streptavidin PE-Cy-5 10min at RT
(all from eBioscience San-Diego CA, USA). Anti-hamster IgG
followed by Streptavidin-Cy-5 served as a measure of non-specific
binding. AMP peptide served as low TCR affinity control. The
cells were analyzed by confocal fluorescence microscopy using
Lab-Tek 8 chambers cover-glass (nunc) with living cells. The
labeled cell samples were observed under a fluorescence confocal
microscope. PE-Cy-5 excitation was done with HeNe laser 633nm
(emission data was collected with filter BA660IF, 660nm long
pass). NBD excitation was done with Ar laser 488nm (emission
data was collected from 505–525nm). In order to quantify the co-
localization percentage we utilized the ‘‘Simple PCI’’ software.
The co-localization percentage was calculated as described below:
Co-localization fluorescence=NBD fluorescence ðÞ |100~
co-localization percentage:
T-cell activation and proliferation
T-cells were plated onto round 96-well plates in medium
containing RPMI-1640 supplemented with 2.5% fetal calf serum
(FCS), 100 U/ml penicillin, 100 mg/ml streptomycin, 50mM2 b-
mercaptoethanol, and 2mM L-glutamine. We used 12610
4 cells of
the T-cell line specific to MOG p35–55, 5610
5 irradiated (3000
rad) spleen cells (APC), and 10 mg/ml of MOG p35–55 were
added to each well. In addition, peptide corresponding to the gp41
TM region was added. Each determination was made at least in
triplicate.
In order to exclude interaction between the examined peptides
and the MOG p35–55 antigen, we initially added the MOG p35–
55 antigen to the APCs in a test tube, and in a second test tube we
added the examined peptides to the T-cells. After 1 hour, we
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For some experiments, T cells were activated with immobilized
anti-CD3 antibodies [51] or PMA/ionomycin as described [3].
After 72 hours, at 37uC in a 7.5% CO2 humidified atmosphere,
the T-cells were pulsed with 1mCi (H
3) thymidine, with a specific
activity of 5.0 Ci/mmol, for 7 hours, and (H
3) thymidine
incorporation was measured using a 96-well plate beta-counter.
The mean cpm 6 Standard Deviation (SD) was calculated for
each quadruplicate or more. The results of T-cell proliferation
experiments are shown as the percentage of T-cell proliferation
inhibition triggered by the antigen in the absence of gp41 TM
peptide. The statistical analyses were performed using ANOVA.
Mice
C57BL/6J mice were purchased from Harlan Olac (Bicester
UK). The mice were maintained in a specific pathogen-free
facility.
Bioinformatics database analysis
To evaluate the occurrence of TCRa CP-like TMDs in viruses,
a dataset of putative viral TMDs was constructed based on the
viral sub-division within the Uniport Knowledge Base, consisting
on the intensively annotated Swiss-Prot database (version 57.10,
total of 29,252 entries) [52]. All sequences containing at least one
TM annotation in the FT field were extracted from the dataset to
create a library of TM viral domains, where every entry is
composed from a distinct putative TMD within a protein. Overall,
the library contained 6175 entries distinct at the sub-species/
variants level. Entries belonging to the same taxonomic species
were grouped into clusters which contained multiple sequences
derived from several sub-species or variants. For our statistical
analysis (Wilcoxon Rank Test) only clusters in which n.3 were
used (overall 2874 entries were grouped into 265 clusters).
Taxonomic clustering of results was conducted according to the
tax ID lineage of each distinct entry. In the next step, a pairwise
alignment of the TCRa CP was performed against each of the
dataset sequences utilizing the EMBOSS package Needle pairwise
global alignment [25] at the (http://www.ebi.ac.uk/Tools/
emboss/align/index.html) server. Alignments parameters were
set using the Blosum40 matrix with gap opening/cost of 10/10
respectively. Results were ranked according to the clusters’ Z-score
(normalized by the mean and standard deviation of the 265
clusters alignment scores) [53] and were analyzed using Matlab
software (MathWorks, Natick,Mass). Statistical significance was
determined according to the Benjamini-Hochberg method
(E(FDR),0.05) [54].
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